These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23153963)

  • 1. Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study.
    De Waele JJ; Tellado JM; Alder J; Reimnitz P; Jensen M; Hampel B; Arvis P
    Int J Antimicrob Agents; 2013 Jan; 41(1):57-64. PubMed ID: 23153963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections.
    Solomkin J; Zhao YP; Ma EL; Chen MJ; Hampel B;
    Int J Antimicrob Agents; 2009 Nov; 34(5):439-45. PubMed ID: 19692210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.
    Goldstein EJ; Solomkin JS; Citron DM; Alder JD
    Clin Infect Dis; 2011 Dec; 53(11):1074-80. PubMed ID: 21998288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial.
    Vehreschild JJ; Moritz G; Vehreschild MJ; Arenz D; Mahne M; Bredenfeld H; Chemnitz J; Klein F; Cremer B; Böll B; Kaul I; Wassmer G; Hallek M; Scheid C; Cornely OA
    Int J Antimicrob Agents; 2012 Feb; 39(2):130-4. PubMed ID: 22169408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections.
    Chen CW; Ming CC; Ma CJ; Shan YS; Yeh YS; Wang JY
    Surg Infect (Larchmt); 2013 Aug; 14(4):389-96. PubMed ID: 23859673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomised controlled trials.
    Mu YP; Liu RL; Wang LQ; Deng X; Zhu N; Wei MD; Wang Y
    Int J Clin Pract; 2012 Feb; 66(2):210-7. PubMed ID: 22257046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential intravenous/oral moxifloxacin monotherapy for complicated skin and skin structure infections: a meta-analysis of randomised controlled trials.
    Chen F; Zheng N; Wang Y; Wen JL; Tu WF; Du YQ; Lin JM
    Int J Clin Pract; 2013 Sep; 67(9):834-42. PubMed ID: 23952463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
    Zervos M; Martinez FJ; Amsden GW; Rothermel CD; Treadway G
    Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of moxifloxacin for the treatment of community-acquired [corrected] complicated intra-abdominal infections in Taiwan.
    Lau YJ; Chen YH; Huang CT; Lee WS; Liu CY; Liu JW; Liu HD; Lee YJ; Chen CW; Ko WC; Hsueh PR
    J Microbiol Immunol Infect; 2012 Feb; 45(1):1-6. PubMed ID: 22244019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
    Ross JD; Cronjé HS; Paszkowski T; Rakoczi I; Vildaite D; Kureishi A; Alefelder M; Arvis P; Reimnitz P;
    Sex Transm Infect; 2006 Dec; 82(6):446-51. PubMed ID: 16723364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
    Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.
    Hadley JA; Mösges R; Desrosiers M; Haverstock D; van Veenhuyzen D; Herman-Gnjidic Z
    Laryngoscope; 2010 May; 120(5):1057-62. PubMed ID: 20422704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections.
    Malangoni MA; Song J; Herrington J; Choudhri S; Pertel P
    Ann Surg; 2006 Aug; 244(2):204-11. PubMed ID: 16858182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
    Wells WG; Woods GL; Jiang Q; Gesser RM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii67-74. PubMed ID: 15150185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
    Giordano P; Song J; Pertel P; Herrington J; Kowalsky S
    Int J Antimicrob Agents; 2005 Nov; 26(5):357-65. PubMed ID: 16229991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.
    Kern WV; Marchetti O; Drgona L; Akan H; Aoun M; Akova M; de Bock R; Paesmans M; Viscoli C; Calandra T
    J Clin Oncol; 2013 Mar; 31(9):1149-56. PubMed ID: 23358983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection.
    Arguedas A; Cespedes J; Botet FA; Blumer J; Yogev R; Gesser R; Wang J; West J; Snyder T; Wimmer W;
    Int J Antimicrob Agents; 2009 Feb; 33(2):163-7. PubMed ID: 18945594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.